Skip to main content
Premium Trial:

Request an Annual Quote

Viravaxx, Medical University of Vienna Partnering on COVID-19 Dx, Vaccine Work

NEW YORK – Austrian biopharma firm Viravaxx said on Tuesday that it is collaborating with the Medical University of Vienna to create a platform for diagnostic and vaccine research into COVID-19.

The collaborators will use a protein microarray comprising the proteome of SARS-CoV-2 to enable high resolution identification of viral antigens that elicit an immune response. Additionally, they are developing an ELISA that will allow them to investigate whether sera from recovered COVID-19 patients are able to neutralize the virus and to map viral epitopes.

The parties plan to use this data to aid the design of vaccine candidates using Viravaxx's peptide-carrier-fusion platform. They will also use the combined microarray and ELISA platforms to study the response to these candidate vaccines in animal models.

"In the current devastating COVID-19-pandemic, two major demands are on everybody’s mind," Rainer Henning, Viravaxx's CEO, said in a statement. "First, there is an urgent need for serological assays which effectively identify protective immunity, so that already-immune people can get back to work and social interactions … Second, a potent vaccine is required, which reliably confers lasting immunity, so that vaccinated people will be protected from future waves of SARS-CoV-2-infections. We at Viravaxx work to answer these demands with our integrated platform."

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.